Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Joel A Klappenbach"'
Autor:
Jianwu Bai, Steven L Smock, George R Jackson, Kenzie D MacIsaac, Yongsheng Huang, Courtney Mankus, Jonathan Oldach, Brian Roberts, Yu-Lu Ma, Joel A Klappenbach, Michael A Crackower, Stephen E Alves, Patrick J Hayden
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0118286 (2015)
Human airway epithelial cells are the principal target of human rhinovirus (HRV), a common cold pathogen that triggers the majority of asthma exacerbations. The objectives of this study were 1) to evaluate an in vitro air liquid interface cultured hu
Externí odkaz:
https://doaj.org/article/63cf64f8100649a6b70ec6bbe21137ad
Autor:
Ping Qiu, Richard Stevens, Bo Wei, Fred Lahser, Anita Y M Howe, Joel A Klappenbach, Matthew J Marton
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0122082 (2015)
Genotyping of hepatitis C virus (HCV) plays an important role in the treatment of HCV. As new genotype-specific treatment options become available, it has become increasingly important to have accurate HCV genotype and subtype information to ensure t
Externí odkaz:
https://doaj.org/article/4eeb3ce82bb34034bdeed8e878c8cc20
Autor:
Elliott B. Nickbarg, Graham Smith, Matthew Richards, Peter Saradjian, Jeannie T. Lee, Patrick J. Curran, Daniel J. Klein, Rodrigo Aguilar, Ali Nahvi, Chad Chamberlin, John P. Santa Maria, Julja Burchard, Noreen F. Rizvi, Joel A. Klappenbach, Peter J. Dandliker, Peter S. Kutchukian
Publikováno v:
SLAS Discovery. 25:384-396
Although the potential value of RNA as a target for new small molecule therapeutics is becoming increasingly credible, the physicochemical properties required for small molecules to selectively bind to RNA remain relatively unexplored. To investigate
Autor:
Kevin W. Johnson, Peter Fuller, Sujal V. Deshmukh, Fang He, Peter Goldenblatt, Lauren Dorosh, Hongbo Zeng, Jason D. Brubaker, Luis E. Torres, Tony Siu, Fiona Elwood, Charles A. Lesburg, Sangita B. Patel, Duan Liu, Elma Kadic, Christopher J. Dinsmore, Xavier Fradera, Lynsey Shaffer, Jonathan R. Young, Lily Y. Moy, Feng Shi, Carla Alpert, Joel A. Klappenbach, Joshua Close, Rafael Fernandez, Hongshi Yu, Nathan Bays, Dawn M. Mampreian
Publikováno v:
Journal of Medicinal Chemistry. 60:9676-9690
The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key paramete
Autor:
Douglas C. Wilson, Namit Kumar, Svetlana Sadekova, Lixia Li, Jerelyn Wong, Kelvin Xi Zhang, Renee Moore, Vanessa M. Peterson, Joel A. Klappenbach, Terrill K. McClanahan
Publikováno v:
Nature Biotechnology. 35:936-939
We present a tool to measure gene and protein expression levels in single cells with DNA-labeled antibodies and droplet microfluidics. Using the RNA expression and protein sequencing assay (REAP-seq), we quantified proteins with 82 barcoded antibodie
Autor:
Donald A. Bergstrom, Luiz M Camargo, Andrey Loboda, Bo Wei, Jeremy Hing, Sanjiv J. Shah, Eva M. Finney, Samuel C. Blackman, Radha Railkar, Amy Harman, Peter Strack, Tim Demuth, Gary A. Herman, Jared Lunceford, Keith Q. Tanis, James S. Hardwick, Joel A. Klappenbach, James Watters, Robert Iannone, Alexei A. Podtelezhnikov
Publikováno v:
Clinical Pharmacology & Therapeutics. 99:370-380
γ-Secretase mediates amyloid production in Alzheimer's disease (AD) and oncogenic activity of Notch. γ-Secretase inhibitors (GSIs) are thus of interest for AD and oncology. A peripheral biomarker of Notch activity would aid determination of the the
Autor:
Pallavi Gandhi, Elaine O’Loughlin, Jacob Marcus, Veeravan Mahadomrongkul, Richard C. Stevens, Jason Da Gilliland, Christopher Ware, Bonnie J. Howell, Keith Q. Tanis, Gonzalo Zeballos Zeballos, Joel A. Klappenbach, Michelle Pearson, Sarah M. Rothman, Christian Mirescu, Matthew E. Kennedy, Roger Smith, Vladislav A. Malkov
Publikováno v:
Journal of Neuroinflammation
Journal of Neuroinflammation, Vol 15, Iss 1, Pp 1-15 (2018)
Journal of Neuroinflammation, Vol 15, Iss 1, Pp 1-15 (2018)
Background Alzheimer’s disease (AD) is a chronic neurodegenerative disease with pathological hallmarks including the formation of extracellular aggregates of amyloid-beta (Aβ) known as plaques and intracellular tau tangles. Coincident with the for
Autor:
Peter J. Dandliker, Hao Tang, Christopher J. Dinsmore, Chi-Sung Chiu, Fiona Elwood, Deborah Slipetz, Jennifer Piesvaux, Sujal V. Deshmukh, Ilona Kariv, Bo-Sheng Pan, Carla Alpert, Nathan Bays, Alan Byford, Alexey Rivkin, Peter Goldenblatt, Irena Ivanovska, Mark E. Scott, Joel A. Klappenbach, Hyun-Hee Lee, David J. Witter, Kalyan Chakravarthy, Lauren Dorosh, Yujie Qu, Brian Kraybill, Mark Zielstorff
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 361(2)
Reversible janus associated kinase (JAK) inhibitors such as tofacitinib and decernotinib block cytokine signaling and are efficacious in treating autoimmune diseases. However, therapeutic doses are limited due to inhibition of other JAK/signal transd
Autor:
Lily Y. Moy, Garfield G. Mingo, Xiomara Fernandez, Yvette Crawley, Janice D Woodhouse, Shanil Keshwani, Gissela Lieber, John C. Anthes, Robbie L. McLeod, Yanlin Jia, Yu-Lu Ma, Johanna Jimenez, Joel A. Klappenbach, Michael Caniga, Milenko Cicmil, Malgorzata A Gil, Nancy Kelly
Publikováno v:
European Journal of Pharmacology. 718:290-298
Accumulating evidence indicates protective actions of mineralocorticoid antagonists (MR antagonists) on cardiovascular pathology, which includes blunting vascular inflammation and myocardial fibrosis. We examined the anti-inflammatory and anti-fibrot
Autor:
Thompson Cd, Maciolek C, Declercq R, Christopher R. Gibson, Tsou Ja, Roger Smith, Wang Yh, Michele Trucksis, Joel A. Klappenbach, Joshua McElwee, Panorchan P, T Laethem, Peggy H. Wong, Jane Harrelson, Vets E, Marian Iwamoto, Peter M. Shaw, John A. Wagner, Gregory J. Opiteck, Garrett Gc, Willson Kj, Prueksaritanont T
Publikováno v:
Clinical Pharmacology and Therapeutics
MK-7246, an antagonist of the chemoattractant receptor on T helper type 2 (Th2) cells, is being developed for the treatment of respiratory diseases. In a first-in-human study, we investigated whether genetic polymorphisms contributed to the marked in